Exagen Inc. (NASDAQ:XGN) Major Shareholder Nmsic Co-Investment Fund, L.P. Sells 200,000 Shares

Exagen Inc. (NASDAQ:XGN) major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $3.30, for a total transaction of $660,000.00. Following the completion of the transaction, the insider now owns 2,108,958 shares in the company, valued at $6,959,561.40. The trade was a 8.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Exagen Stock Down 2.5 %

NASDAQ:XGN traded down $0.10 during trading hours on Wednesday, hitting $3.84. The stock had a trading volume of 23,799 shares, compared to its average volume of 46,110. The company has a market cap of $67.74 million, a PE ratio of -4.16 and a beta of 1.35. The business has a 50 day simple moving average of $2.94 and a two-hundred day simple moving average of $2.52. Exagen Inc. has a 1-year low of $1.30 and a 1-year high of $4.83. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The firm had revenue of $12.51 million for the quarter, compared to analyst estimates of $13.55 million. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. During the same quarter in the previous year, the business posted ($0.31) EPS. Analysts predict that Exagen Inc. will post -0.87 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, William Blair reissued an “outperform” rating on shares of Exagen in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Stonepine Capital Management LLC grew its position in shares of Exagen by 49.0% during the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after buying an additional 175,701 shares in the last quarter. Verus Capital Partners LLC acquired a new position in Exagen during the 3rd quarter worth $39,000. Palumbo Wealth Management LLC increased its position in shares of Exagen by 14.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after purchasing an additional 9,695 shares during the last quarter. Creative Planning acquired a new stake in shares of Exagen in the 3rd quarter valued at about $110,000. Finally, Renaissance Technologies LLC lifted its holdings in Exagen by 93.3% during the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after buying an additional 45,476 shares during the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).